Bristol-Myers Squibb Company Ce (CELG-RI)
Market Closed
2 Sep, 20:00
NYSE NYSE Primary $
0. 15
+0.02
+13.8462%
$
244.72M Market Cap
- P/E Ratio
- Div Yield
60,636 Volume
- Eps
$ 0.13
Previous Close Want to track CELG-RI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CELG-RI closed today higher at $0.15, an increase of 13.8462% from yesterday's close, completing a monthly increase of 44.3902% or $0.05. Over the past 12 months, CELG-RI stock gained 105.5556%.
CELG-RI is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Bristol-Myers Squibb Company Ce Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 166 | $15 | $24.57 | $9.57 | 63.8% |
 Matthew Cochran Atlantic Edge Private Wealth Management, LLC | 16 | $0.88 | $1.5 | $0.62 | 70.45% |
 Purkiss Capital Advisors LLC Purkiss Capital Advisors LLC | 26,450 | $1,296 | $3,491.4 | $2,195.4 | 169.4% |
Bristol-Myers Squibb Company Ce (CELG-RI) FAQ
What is the stock price today?
The current price is $0.15.
On which exchange is it traded?
Bristol-Myers Squibb Company Ce is listed on NYSE.
What is its stock symbol?
The ticker symbol is CELG-RI.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 244.72M.
Has Bristol-Myers Squibb Company Ce ever had a stock split?
No, there has never been a stock split.
Bristol-Myers Squibb Company Ce Profile
| Pharmaceuticals Industry | Healthcare Sector | Christopher S. Boerner CEO | NYSE Exchange | 110122140 CUSIP |
| US Country | 34,100 Employees | - Last Dividend | - Last Split | - IPO Date |
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
Contact Information
Address: Route 206 & Province Line Road
Phone: +1 609 252 4000
Website: http://www.bms.com
